Literature DB >> 18927069

Lipopolysaccharide-induced immune responses in relation to the TLR4(Asp299Gly) gene polymorphism.

Anna Lundberg1, Lars Andersson Wikberg, Jorma Ilonen, Outi Vaarala, Malin Fagerås Böttcher.   

Abstract

Altered microbial exposure is a possible explanation for the increase of allergies in the Western world. However, genetic factors influence microbially induced immune responses. We have investigated the TLR4(Asp299Gly) gene polymorphism and its possible association with receptor expression of circulating peripheral blood monocytes and the in vitro cytokine responses and phosphorylation of intracellular signaling proteins in peripheral blood mononuclear cells (PBMC) stimulated with lipopolysaccharide (LPS) from Escherichia coli and Salmonella enterica serotype Typhimurium. We studied 34 of the predominant haplotype TLR4 Asp299 (AA) and 8 heterozygote Asp299Gly (AG) individuals. TLR4 expression levels were similar in the two genotype groups. Serovar Typhimurium LPS induced interleukin-12p70 from PBMC, and the degree of phosphorylation of the intracellular signaling protein IkappaBalpha in PBMC was lower in the AG than the AA group (P=0.03 and P=0.04, respectively). These results were not seen, however, when PMBC were stimulated with E. coli-derived LPS. Based on these results, we propose that TLR4(Asp299Gly) gene polymorphism and the bacterial origin of LPS should be considered when environmental LPS exposure is evaluated in disease risk or protection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927069      PMCID: PMC2593161          DOI: 10.1128/CVI.00241-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

Review 1.  Toll receptors in innate immunity.

Authors:  J L Imler; J A Hoffmann
Journal:  Trends Cell Biol       Date:  2001-07       Impact factor: 20.808

2.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.

Authors:  N C Arbour; E Lorenz; B C Schutte; J Zabner; J N Kline; M Jones; K Frees; J L Watt; D A Schwartz
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

3.  The cytokine synthesis by heterozygous carriers of the Toll-like receptor 4 Asp299Gly polymorphism does not differ from that of wild type homozygotes.

Authors:  Michael Heesen; Brunhilde Bloemeke; Dagmar Kunz
Journal:  Eur Cytokine Netw       Date:  2003 Oct-Dec       Impact factor: 2.737

4.  Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood.

Authors:  Sonja von Aulock; Nicolas W J Schröder; Katja Gueinzius; Stephanie Traub; Sebastian Hoffmann; Kathrin Graf; Stefanie Dimmeler; Thomas Hartung; Ralf R Schumann; Corinna Hermann
Journal:  J Infect Dis       Date:  2003-08-28       Impact factor: 5.226

Review 5.  Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease.

Authors:  Ross Lazarus; Donata Vercelli; Lyle J Palmer; Walt J Klimecki; Edwin K Silverman; Brent Richter; Alberto Riva; Marco Ramoni; Fernando D Martinez; Scott T Weiss; David J Kwiatkowski
Journal:  Immunol Rev       Date:  2002-12       Impact factor: 12.988

6.  Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes.

Authors:  Benjamin A Raby; Walter T Klimecki; Catherine Laprise; Yannick Renaud; Janet Faith; Mathieu Lemire; Celia Greenwood; Katherine M Weiland; Christoph Lange; Lyle J Palmer; Ross Lazarus; Donata Vercelli; David J Kwiatkowski; Edwin K Silverman; Fernando D Martinez; Thomas J Hudson; Scott T Weiss
Journal:  Am J Respir Crit Care Med       Date:  2002-09-25       Impact factor: 21.405

Review 7.  The role of NF-kappaB in the regulation of cell stress responses.

Authors:  Tieli Wang; Xia Zhang; Jian Jian Li
Journal:  Int Immunopharmacol       Date:  2002-10       Impact factor: 4.932

8.  Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings.

Authors:  Olivier Michel; Tricia D LeVan; Debbie Stern; Mieke Dentener; Jörgen Thorn; Daniele Gnat; M Lena Beijer; Pascale Cochaux; Patrick G Holt; Fernando D Martinez; Ragnar Rylander
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

9.  Impaired maturation of monocyte-derived dendritic cells from birch allergic individuals in association with birch-specific immune responses.

Authors:  R Casas; S Skarsvik; A Lindström; O Zetterström; K Duchén
Journal:  Scand J Immunol       Date:  2007-09-14       Impact factor: 3.487

10.  Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling.

Authors:  Clett Erridge; John Stewart; Ian R Poxton
Journal:  J Exp Med       Date:  2003-06-09       Impact factor: 14.307

View more
  5 in total

Review 1.  Impact of direct soil exposures from airborne dust and geophagy on human health.

Authors:  David Sing; Charles F Sing
Journal:  Int J Environ Res Public Health       Date:  2010-03-19       Impact factor: 3.390

Review 2.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

3.  Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis.

Authors:  Paula Piñero; Oriol Juanola; Esther Caparrós; Pedro Zapater; Paula Giménez; José M González-Navajas; José Such; Rubén Francés
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

4.  The Toll-like Receptor 4 Polymorphism Asp299Gly Is Associated with an Increased Risk of Ovarian Cancer.

Authors:  Katarzyna D Kania; Daria Haręża; Jacek R Wilczyński; Miłosz Wilczyński; Dariusz Jarych; Andrzej Malinowski; Edyta Paradowska
Journal:  Cells       Date:  2022-10-05       Impact factor: 7.666

5.  The Toll-like receptor 4 polymorphism Asp299Gly but not Thr399Ile influences TLR4 signaling and function.

Authors:  Huaicong Long; Brian P O'Connor; Rachel L Zemans; Xiaofang Zhou; Ivana V Yang; David A Schwartz
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.